Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
CRISPR Therapeutics AG - Common Shares
(NQ:
CRSP
)
40.72
+0.34 (+0.84%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about CRISPR Therapeutics AG - Common Shares
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy?
Today 12:25 EST
Via
The Motley Fool
1 big new Green Flag for CRISPR Therapeutics' Stock
December 20, 2024
Via
The Motley Fool
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
December 20, 2024
The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future.
Via
Investor's Business Daily
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?
December 17, 2024
Via
The Motley Fool
3 Things You Need to Know if You Buy CRISPR Therapeutics Today
December 14, 2024
Via
The Motley Fool
2 Biotech Stocks to Buy Hand Over Fist in December
December 07, 2024
Via
The Motley Fool
Where Will CRISPR Therapeutics Be in 3 Years?
November 15, 2024
Via
The Motley Fool
3 of the Best Growth Stocks You Can Buy for Less than $100
December 05, 2024
Via
The Motley Fool
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More than 65%
November 30, 2024
Via
The Motley Fool
Cathie Wood Sees Tesla As 'Largest AI Project On Earth' — Here's Why She's Not Worried About Tech Investments
November 29, 2024
Cathie Wood, founder and CEO of ARK Investment Management LLC, defended the future of artificial intelligence investments while highlighting Tesla Inc. as a cornerstone of technological innovation...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
November 26, 2024
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts
November 25, 2024
Editas Medicine faces a downgrade to Underperform from BofA, citing competition, limited catalysts, and a reduced price target of $1 from $13.
Via
Benzinga
Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?
November 24, 2024
Via
The Motley Fool
3 Monster Stocks in the Making
November 23, 2024
Via
The Motley Fool
Deciphering Disruption: Inside Cathie Wood's Latest Plays
November 16, 2024
Cathie Wood's recent stock market activity offers a glimpse into her evolving investment strategy and the potential of disruptive technologies.
Via
MarketBeat
Topics
Artificial Intelligence
ETFs
Exposures
Artificial Intelligence
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
November 16, 2024
Via
The Motley Fool
3 Unstoppable Growth Stocks I'm Loading $25,000 Each Into by 2029
November 13, 2024
These three emerging technology leaders are pioneering quantum computing, gene editing, and electric aviation.
Via
The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
November 08, 2024
The rock star fund investor made a lot of big moves on Thursday.
Via
The Motley Fool
Smaller Cap Biotechs Are In Season: How Are We Doing?
November 07, 2024
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.
Via
Talk Markets
3 Companies Building Tomorrow's Game-Changing Technologies
November 05, 2024
These pioneering companies are transforming delivery, medicine, and space access--potentially creating massive opportunities for early investors.
Via
The Motley Fool
Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers
November 02, 2024
It won't be able to be profitable without hitting its targets for both of these figures.
Via
The Motley Fool
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
October 31, 2024
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings.
Via
Benzinga
Topics
ETFs
Stocks
Exposures
US Equities
12 High-Growth Stocks That Could Deliver Parabolic Returns
October 28, 2024
These 12 innovative companies could deliver exponential returns over the next quarter century.
Via
The Motley Fool
The Ultimate Biotech Stock to Buy With $50 Right Now
October 26, 2024
This company might be worth far more than many realize.
Via
The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
October 22, 2024
The aggressive growth icon kicked off the new trading week by buying some of her favorite stocks.
Via
The Motley Fool
Why We Buy Stocks
October 21, 2024
Is fear of missing out (FOMO) controlling your portfolio?
Via
The Motley Fool
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
October 19, 2024
Yes, bargains can still be found in the stock market.
Via
The Motley Fool
Why I Keep Buying These 14 Incredible Growth Stocks
October 16, 2024
This diverse set of growth stocks offers tremendous opportunities in the fields of AI, space, biotech, and emerging industries.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Is CRISPR Therapeutics Stock a Buy?
October 13, 2024
The markets this biotech is looking to enter could be extremely lucrative.
Via
The Motley Fool
2 Biotech Stocks That Are Screaming Buys This Month
October 12, 2024
They won't remain southbound forever.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.